Addiction of High Dose of Benzodiazepine: Verona Detox Approach With Flumazenil.
addiction
benzodiazepine
detox
flumazenil
high dose
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
01
2022
accepted:
07
03
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
epublish
Résumé
Since the 1990s there has been evidence of the significant role Flumazenil (FLU) has in benzodiazepines (BZD) detoxes. The Verona Detox approach has been developed for high dose BZD and Z-drug detoxification via continuous subcutaneous infusion of FLU, a selective BZD receptor antagonist acting on the BZD subunit of the GABA-A receptor. Flumazenil is licensed in the United Kingdom and other countries to treat only BZD overdose although numerous studies have demonstrated its effectiveness in rapidly resetting GABA-A receptors, quickly reducing tolerance and dependence from BZD, and providing a safe and rapid detox from benzodiazepines. The aim of this article is to provide all healthcare professional who are interested in BZD detoxification with an approach and clear practical information on how to administer FLU. In this article we outline the approach in detail, describing all medical and nursing procedures day by day. This detox treatment is indicated for patients abusing from at least 5 Defined Daily Dose (DDD) of BZDs or Z-drugs. The process lasts 7 days, and is conducted under medical supervision (daily reviews) and continuous nursing (24/7). During this period, 7mg of FLU is administered (1 mg/24) through an elastomeric pump, via continuous subcutaneous infusion. To this day, the largest database of FLU detoxification was published by our group, showing how this treatment is safe, with very little side effects even in patients with significant medical comorbidities.
Identifiants
pubmed: 35432044
doi: 10.3389/fpsyt.2022.857376
pmc: PMC9008883
doi:
Types de publication
Journal Article
Langues
eng
Pagination
857376Informations de copyright
Copyright © 2022 Casari, Metastasio, Zamboni, Biasioli, Campagnari and Lugoboni.
Déclaration de conflit d'intérêts
AM was employed by Camden and Islington NHS Foundation Trust. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2017 Jun 15;376(24):2399
pubmed: 28614688
Dtsch Arztebl Int. 2015 Jan 5;112(1-2):1-7
pubmed: 25613443
Subst Abus. 2012;33(2):195-8
pubmed: 22489594
Psychopharmacologia. 1961 Feb 20;2:63-8
pubmed: 13715373
Int J Methods Psychiatr Res. 2021 Dec;30(4):e1888
pubmed: 34331787
Drug Alcohol Depend. 2009 Sep 1;104(1-2):140-6
pubmed: 19515515
Can J Hosp Pharm. 2022 Winter;75(1):46-53
pubmed: 34987263
J Psychopharmacol. 2009 Jun;23(4):401-9
pubmed: 19164495
N Engl J Med. 2017 Mar 23;376(12):1147-1157
pubmed: 28328330
J Psychopharmacol. 2017 Oct;31(10):1369-1373
pubmed: 28613124
Addiction. 2010 Nov;105(11):1877-8
pubmed: 21064248
Addiction. 2011 Dec;106(12):2086-109
pubmed: 21714826
Epilepsia. 2012 Dec;53 Suppl 7:26-33
pubmed: 23153207
J Psychopharmacol. 2021 Mar;35(3):211-220
pubmed: 33426982
Psychiatry Res. 2017 May;251:197-203
pubmed: 28213190
Int Clin Psychopharmacol. 2007 Sep;22(5):292-8
pubmed: 17690598
Int Clin Psychopharmacol. 1996 Jun;11(2):81-8
pubmed: 8803645
J Psychopharmacol. 2014 Jul;28(7):703-6
pubmed: 24554692
Psychother Psychosom. 2015;84(5):273-83
pubmed: 26278327
Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):81-91
pubmed: 22175232
J Psychopharmacol. 2013 Feb;27(2):222-7
pubmed: 22596209
Epilepsy Behav. 2012 Feb;23(2):168-70
pubmed: 22200495
Br J Clin Pharmacol. 2014 Feb;77(2):285-94
pubmed: 23126253
Front Psychiatry. 2021 Mar 18;12:646038
pubmed: 33815177
Psychiatry Res. 2012 Aug 15;198(3):457-62
pubmed: 22424905
Addict Biol. 2002 Oct;7(4):385-95
pubmed: 14578014
Int Clin Psychopharmacol. 2005 Sep;20(5):285-7
pubmed: 16096519
J Psychopharmacol. 2016 Oct;30(10):1047-53
pubmed: 27166362